In addition, TAVO412 also demonstrated activities in tumor types with dysregulated EGFR, c-Met, and VEGF signaling, such as head and neck squamous cell carcinoma (HNSCC) (7–9), ovarian cancer (OC) (10), hepatocellular carcinoma (HCC) (11), and small cell lung cancer (SCLC) (12). This evidence concerns the gene MET and hepatocellular carcinoma.